Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMSTEFK)

Drug Name

SKB264 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Tumor associated calcium signal transducer 2 (TACSTD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sacituzumab govitecan	DMUWFD8	Breast cancer	2C60-2C65	Approved	[2]
YH012	DMG3WBJ	Aggressive cancer	2A00-2F9Z	Investigative	[3]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tumor associated calcium signal transducer 2 (TACSTD2)	TTP2HE5	TACD2_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health.
2	Sacituzumab Govitecan: First Approval. Drugs. 2020 Jul;80(10):1019-1025.
3	Clinical pipeline report, company report or official report of Biocytogen